ANKRD28 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- ANKRD28 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb101221
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ANKRD28 antibody Polyclonal Antibodies Primary antibodies
Related genes to: ANKRD28 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- ANKRD28 NIH gene
- Name:
- ankyrin repeat domain 28
- Previous symbol:
- -
- Synonyms:
- KIAA0379, PITK, PP6-ARS-A, PPP1R65
- Chromosome:
- 3p25.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-26
- Date modifiied:
- 2015-09-11
Related products to: ANKRD28 antibody Polyclonal Antibodies Primary antibodies
Related articles to: ANKRD28 antibody Polyclonal Antibodies Primary antibodies
- - Source: PubMed
Publication date: 2025/08/05
Cordier FleurFerdinande LiesbethLoontiens SiebeVan der Meulen JoniVan Dorpe JoCreytens David - Multiple myeloma (MM) remains an incurable disease primarily due to the emergence of drug resistance, and the underlying mechanisms remain unclear. Extrachromosomal circular DNAs (eccDNAs) are prevalent in cancer genomes of both coding and non-coding regions. However, the role of non-coding eccDNA regions that serve as enhancers has been largely overlooked. Here, genome-wide profiling of serum eccDNAs from donors and MM patients who responded well or poorly to bortezomib-lenalidomide-dexamethasone (VRd) therapy is characterized. A high copy number of eccDNA ANKRD28 (eccANKRD28) predicts poor therapy response and prognosis but enhanced transcriptional activity. Established VRd-resistant MM cell lines exhibit a higher abundance of eccANKRD28, and CRISPR/Cas9-mediated elevation of eccANKRD28 desensitizes bortezomib and lenalidomide treatment both in vitro and in vivo. Integrated multi-omics analysis (H3K27ac ChIP-seq, scRNA-seq, scATAC-seq, CUT&Tag, et al.) identifies eccANKRD28 as an active enhancer involved in drug resistance driven by the key transcription factor, POU class 2 homeobox 2 (POU2F2). POU2F2 interacts with sequence-specific eccANKRD28 as well as RUNX1 and RUNX2 motifs to form the protein complex, which activates the promoter of oncogenes, including IRF4, JUNB, IKZF3, RUNX3, and BCL2. This study elucidates the potential transcriptional network of enhancer eccANKRD28 in MM drug resistance from a previously unrecognized epigenetic perspective. - Source: PubMed
Publication date: 2025/04/01
Chen BinzhenLiu JiaZhang YaoxinShi ChangmingZhu DiZhang GuoqiangXiao FeiZhong LuZhang MinyueNg Lai GuanHuang HonghuiLu TingtingHou Jian - Colorectal cancer (CRC) remains a significant global health concern, demanding a more profound comprehension of its molecular foundations for the development of improved therapeutic strategies. This study aimed to elucidate the role of protein phosphatase 6 (PP6), a member of the type 2A protein phosphatase family, in CRC. Protein phosphatase 6 functions as a heterotrimer with a catalytic subunit (PP6c), regulatory subunits (PP6Rs; PP6R1, PP6R2, and PP6R3), and scaffold subunits (ANKRD28, ANKRD44, and ANKRD52). Elevated PP6c expression has been identified in CRC tissues compared to normal mucosa, aligning with its potential involvement in CRC pathogenesis. PP6c knockdown resulted in decreased colony-forming ability and in vivo proliferation of various CRC cell lines. Transcriptome analysis revealed that PP6c knockdown resulted in altered expression of genes associated with cancer stemness. Notably, the PP6c-PP6R3 complex is a key player in regulating cancer stem cell (CSC) markers. Additionally, increased PP6c expression was observed in CSC-like cells induced by sphere formation, implicating the role of PP6c in CSC maintenance. This study highlights the role of PP6c in CRC and suggests that it is a potential therapeutic target disrupting a pathway critical for CRC progression and stem cell maintenance. - Source: PubMed
Publication date: 2024/07/16
Fujiwara NobuyukiTsunedomi RyouichiKimura YutaNakajima MasaoTomochika ShinobuEnjoji ShuheiOhama TakashiSato KoichiNagano Hiroaki - Diabetic nephropathy (DN) is a severe complication of diabetes that affects the kidneys. Disulfidptosis, a newly defined type of programmed cell death, has emerged as a potential area of interest, yet its significance in DN remains unexplored. - Source: PubMed
Publication date: 2024/07/03
Wang GuoyiZhao JinwenZhou MinLu HaiyuanMao Fei - With the advent of next-generation sequencing, an increasing number of cases of de novo variants in domestic animals have been reported in scientific literature primarily associated with clinically severe phenotypes. The emergence of new variants at each generation is a crucial aspect in understanding the pathology of early-onset diseases in animals and can provide valuable insights into similar diseases in humans. With the aim of collecting deleterious de novo variants in domestic animals, we searched the scientific literature and compiled reports on 42 de novo variants in 31 genes in domestic animals. No clear disease-associated phenotype has been established in humans for three of these genes (NUMB, ANKRD28 and KCNG1). For the remaining 28 genes, a strong similarity between animal and human phenotypes was recognized from available information in OMIM and OMIA, revealing the importance of comparative studies and supporting the use of domestic animals as natural models for human diseases, in line with the One Health approach. - Source: PubMed
Publication date: 2024/02/07
Azevedo LuísaAmaro Andreia PNiza-Ribeiro JoãoLopes-Marques Mónica